AR011278A1 - Una composicion y un medicamento que comprenden derivados amino acidos y un factor neutrofico para estimular el crecimiento de neuritas en celulasnerviosas - Google Patents

Una composicion y un medicamento que comprenden derivados amino acidos y un factor neutrofico para estimular el crecimiento de neuritas en celulasnerviosas

Info

Publication number
AR011278A1
AR011278A1 ARP970105318A ARP970105318A AR011278A1 AR 011278 A1 AR011278 A1 AR 011278A1 AR P970105318 A ARP970105318 A AR P970105318A AR P970105318 A ARP970105318 A AR P970105318A AR 011278 A1 AR011278 A1 AR 011278A1
Authority
AR
Argentina
Prior art keywords
branched
straight
alkyl
alkenyl
alkynyl
Prior art date
Application number
ARP970105318A
Other languages
English (en)
Spanish (es)
Original Assignee
Vertex Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25009484&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR011278(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Vertex Pharma filed Critical Vertex Pharma
Publication of AR011278A1 publication Critical patent/AR011278A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Psychology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
ARP970105318A 1996-11-13 1997-11-13 Una composicion y un medicamento que comprenden derivados amino acidos y un factor neutrofico para estimular el crecimiento de neuritas en celulasnerviosas AR011278A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/748,447 US5840736A (en) 1996-11-13 1996-11-13 Methods and compositions for stimulating neurite growth

Publications (1)

Publication Number Publication Date
AR011278A1 true AR011278A1 (es) 2000-08-16

Family

ID=25009484

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP970105318A AR011278A1 (es) 1996-11-13 1997-11-13 Una composicion y un medicamento que comprenden derivados amino acidos y un factor neutrofico para estimular el crecimiento de neuritas en celulasnerviosas

Country Status (32)

Country Link
US (3) US5840736A (en:Method)
EP (1) EP0946190B1 (en:Method)
JP (1) JP2001504470A (en:Method)
KR (1) KR100544451B1 (en:Method)
CN (1) CN1168442C (en:Method)
AP (1) AP9901518A0 (en:Method)
AR (1) AR011278A1 (en:Method)
AT (1) ATE250424T1 (en:Method)
AU (1) AU724833B2 (en:Method)
BG (1) BG64670B1 (en:Method)
BR (1) BR9712765A (en:Method)
CA (1) CA2270634A1 (en:Method)
CO (1) CO4930260A1 (en:Method)
CZ (1) CZ296058B6 (en:Method)
DE (1) DE69725169T2 (en:Method)
DK (1) DK0946190T3 (en:Method)
EA (1) EA004247B1 (en:Method)
ES (1) ES2206753T3 (en:Method)
HU (1) HU226728B1 (en:Method)
IL (1) IL129555A (en:Method)
IN (1) IN183740B (en:Method)
IS (1) IS2057B (en:Method)
NO (1) NO328030B1 (en:Method)
NZ (1) NZ335394A (en:Method)
PL (1) PL190903B1 (en:Method)
PT (1) PT946190E (en:Method)
SK (1) SK284535B6 (en:Method)
TR (1) TR199901034T2 (en:Method)
TW (1) TW513302B (en:Method)
UA (1) UA63926C2 (en:Method)
WO (1) WO1998020891A1 (en:Method)
ZA (1) ZA9710256B (en:Method)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5859031A (en) * 1995-06-07 1999-01-12 Gpi Nil Holdings, Inc. Small molecule inhibitors of rotamase enzyme activity
US5780484A (en) * 1996-11-13 1998-07-14 Vertex Pharmaceuticals Incorporated Methods for stimulating neurite growth with piperidine compounds
US6242468B1 (en) 1997-02-27 2001-06-05 Jia-He Li Carbamate and urea compositions and neurotrophic uses
US6514686B2 (en) 1997-04-28 2003-02-04 The University Of British Columbia Method and composition for modulating amyloidosis
US5945441A (en) 1997-06-04 1999-08-31 Gpi Nil Holdings, Inc. Pyrrolidine carboxylate hair revitalizing agents
US20010049381A1 (en) 1997-06-04 2001-12-06 Gpl Nil Holdings, Inc., Pyrrolidine derivative hair growth compositions and uses
US6852496B1 (en) 1997-08-12 2005-02-08 Oregon Health And Science University Methods of screening for agents that promote nerve cell growth
US5968921A (en) * 1997-10-24 1999-10-19 Orgegon Health Sciences University Compositions and methods for promoting nerve regeneration
US6331537B1 (en) 1998-06-03 2001-12-18 Gpi Nil Holdings, Inc. Carboxylic acids and carboxylic acid isosteres of N-heterocyclic compounds
CA2334002A1 (en) 1998-06-03 1999-12-09 Mark H. Norman N-linked sulphonamides of n-heterocyclic carboxylic acids or carboxylic acid isosteres
AP2001002052A0 (en) 1998-07-17 2001-03-31 Agouron Pharma Compounds, compositions, and methods for stimulating neuronal growth and elongation
GB9815880D0 (en) 1998-07-21 1998-09-16 Pfizer Ltd Heterocycles
US6395758B1 (en) 1998-08-14 2002-05-28 Gpi Nil Holdings, Inc. Small molecule carbamates or ureas for vision and memory disorders
US6218423B1 (en) 1998-08-14 2001-04-17 Gpi Nil Holdings, Inc. Pyrrolidine derivatives for vision and memory disorders
US7338976B1 (en) 1998-08-14 2008-03-04 Gpi Nil Holdings, Inc. Heterocyclic esters or amides for vision and memory disorders
US6462072B1 (en) 1998-09-21 2002-10-08 Gpi Nil Holdings, Inc. Cyclic ester or amide derivatives
US6307049B1 (en) 1998-09-30 2001-10-23 The Procter & Gamble Co. Heterocyclic 2-substituted ketoamides
US6300341B1 (en) 1998-09-30 2001-10-09 The Procter & Gamble Co. 2-substituted heterocyclic sulfonamides
US6228872B1 (en) * 1998-11-12 2001-05-08 Bristol-Myers Squibb Company Neurotrophic diamide and carbamate agents
EP1135105B1 (en) * 1998-12-09 2005-03-02 Chiron Corporation Use of a neurologic agent for the manufacture of a medicament for the treatment of a central nervous system disorder
JP2002534414A (ja) * 1999-01-08 2002-10-15 バーテックス ファーマシューティカルズ インコーポレイテッド 医薬の製造に有用な中間体の形成方法
WO2001002368A1 (en) * 1999-07-06 2001-01-11 Vertex Pharmaceuticals Incorporated N-heterocyclic derivatives with neuronal activity
US6734211B1 (en) 1999-07-09 2004-05-11 Oregon Health & Sciences University Compositions and methods for promoting nerve regeneration
MXPA02001095A (es) * 1999-07-30 2002-08-20 Vertex Pharma Derivados de amina ciclicos y aciclicos.
CA2386579A1 (en) * 1999-11-12 2001-05-25 Alcon, Inc. Neurophilin ligands for treating ocular conditions
US7253169B2 (en) 1999-11-12 2007-08-07 Gliamed, Inc. Aza compounds, pharmaceutical compositions and methods of use
US6417189B1 (en) 1999-11-12 2002-07-09 Gpi Nil Holdings, Inc. AZA compounds, pharmaceutical compositions and methods of use
US6818643B1 (en) 1999-12-08 2004-11-16 Bristol-Myers Squibb Company Neurotrophic bicyclic diamides
US7060676B2 (en) * 1999-12-20 2006-06-13 Trustees Of Tufts College T. cruzi-derived neurotrophic agents and methods of use therefor
DE60026568D1 (de) 1999-12-21 2006-05-04 Mgi Gp Inc Hydantoin derivate, pharmazeutische zusammensetzungen und verfahren zu ihrer verwendung
US6555573B2 (en) 2000-12-21 2003-04-29 The Quigley Corporation Method and composition for the topical treatment of diabetic neuropathy
AU2002259305A1 (en) * 2001-05-25 2002-12-09 Cornell Research Foundation, Inc. High affinity ligand for p75 neurotrophin receptor
FR2825273B1 (fr) * 2001-05-29 2006-11-24 Oreal Composition pour le traitement des signes cutanes du vieillissement
WO2002096420A2 (en) * 2001-05-29 2002-12-05 Guilford Pharmaceuticals Inc. Method for treating nerve injury caused by surgery
US7435725B2 (en) * 2001-11-06 2008-10-14 The Quigly Corporation Oral compositions and methods for prevention, reduction and treatment of radiation injury
US20030105027A1 (en) * 2001-11-06 2003-06-05 Rosenbloom Richard A. Nutritional supplements and methods for prevention, reduction and treatment of radiation injury
US20030118536A1 (en) * 2001-11-06 2003-06-26 Rosenbloom Richard A. Topical compositions and methods for treatment of adverse effects of ionizing radiation
WO2003041655A2 (en) * 2001-11-13 2003-05-22 Loi Tran Therapeutic agent composition and method of use
US7232798B2 (en) 2001-11-13 2007-06-19 Tran Loi H Neuroprotection and neuroegenisis by administering cyclic prolyl glycine
US20100247483A1 (en) * 2001-11-13 2010-09-30 Tran Loi H Therapeutic agent composition and method of use
US7083813B2 (en) * 2002-11-06 2006-08-01 The Quigley Corporation Methods for the treatment of peripheral neural and vascular ailments
US8841326B2 (en) 2004-02-12 2014-09-23 Stc.Unm Therapeutic curcumin derivatives
CA2637707A1 (en) * 2006-02-02 2007-08-09 Rinat Neuroscience Corporation Methods for treating obesity by administering a trkb antagonist
US20070248611A1 (en) * 2006-02-02 2007-10-25 Pfizer Inc Methods wanted for treating unwanted weight loss or eating disorders by administering a trkb agonist
US20100086997A1 (en) * 2006-12-20 2010-04-08 Rinat Enuroscience Corp TrkB Agonists for Treating Autoimmune Disorders
US20090018151A1 (en) * 2007-02-23 2009-01-15 Ezekiel Fink Topical Treatment of Peripheral diabetic complications
BR112020023252A2 (pt) 2018-05-15 2021-02-23 Lloyd Hung Loi Tran composição do agente terapêutico e método de uso para tratamento de deficiência cognitiva leve, depressão e distúrbios psicológicos.

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5798355A (en) 1995-06-07 1998-08-25 Gpi Nil Holdings, Inc. Inhibitors of rotamase enzyme activity
IL115685A (en) * 1994-11-16 2000-08-31 Vertex Pharma Amino acid derivatives pharmaceutical compositions containing the same and processes for the preparation thereof
US5543423A (en) * 1994-11-16 1996-08-06 Vertex Pharmaceuticals, Incorporated Amino acid derivatives with improved multi-drug resistance activity
US5696135A (en) * 1995-06-07 1997-12-09 Gpi Nil Holdings, Inc. Inhibitors of rotamase enzyme activity effective at stimulating neuronal growth
US5859031A (en) * 1995-06-07 1999-01-12 Gpi Nil Holdings, Inc. Small molecule inhibitors of rotamase enzyme activity
US5614547A (en) * 1995-06-07 1997-03-25 Guilford Pharmaceuticals Inc. Small molecule inhibitors of rotamase enzyme
US6037370A (en) * 1995-06-08 2000-03-14 Vertex Pharmaceuticals Incorporated Methods and compositions for stimulating neurite growth
US5801197A (en) 1995-10-31 1998-09-01 Gpi Nil Holdings, Inc. Rotamase enzyme activity inhibitors
US5811434A (en) * 1996-11-13 1998-09-22 Vertex Pharmacueticals Incorporated Methods and compositions for stimulating neurite growth
CN104718162B (zh) * 2012-09-28 2017-11-21 Dic株式会社 α‑氧化铝微粒以及其制造方法

Also Published As

Publication number Publication date
HK1022851A1 (en) 2000-08-25
NZ335394A (en) 2000-06-23
SK284535B6 (sk) 2005-06-02
BG64670B1 (bg) 2005-11-30
KR20000068962A (ko) 2000-11-25
DK0946190T3 (da) 2003-12-08
US6172086B1 (en) 2001-01-09
AU724833B2 (en) 2000-09-28
IL129555A (en) 2005-08-31
DE69725169T2 (de) 2004-07-15
HU226728B1 (en) 2009-08-28
PL333270A1 (en) 1999-11-22
CZ296058B6 (cs) 2006-01-11
JP2001504470A (ja) 2001-04-03
KR100544451B1 (ko) 2006-01-24
SK62899A3 (en) 2000-04-10
CN1168442C (zh) 2004-09-29
PT946190E (pt) 2004-02-27
CN1239433A (zh) 1999-12-22
BG103429A (en) 2000-04-28
AU5258998A (en) 1998-06-03
NO992138L (no) 1999-07-13
TR199901034T2 (xx) 1999-07-21
NO328030B1 (no) 2009-11-16
ES2206753T3 (es) 2004-05-16
US5840736A (en) 1998-11-24
IS2057B (is) 2005-10-14
BR9712765A (pt) 1999-10-26
EP0946190B1 (en) 2003-09-24
CO4930260A1 (es) 2000-06-27
CZ168399A3 (cs) 1999-08-11
WO1998020891A1 (en) 1998-05-22
IL129555A0 (en) 2000-02-29
ZA9710256B (en) 1998-05-28
ATE250424T1 (de) 2003-10-15
HUP0001219A2 (hu) 2000-11-28
NO992138D0 (no) 1999-05-03
HUP0001219A3 (en) 2001-12-28
US6284778B1 (en) 2001-09-04
TW513302B (en) 2002-12-11
UA63926C2 (uk) 2004-02-16
IS5032A (is) 1999-04-21
EA004247B1 (ru) 2004-02-26
AP9901518A0 (en) 1999-06-30
PL190903B1 (pl) 2006-02-28
IN183740B (en:Method) 2000-04-01
EP0946190A1 (en) 1999-10-06
DE69725169D1 (de) 2003-10-30
EA199900464A1 (ru) 2000-02-28
CA2270634A1 (en) 1998-05-22

Similar Documents

Publication Publication Date Title
AR011278A1 (es) Una composicion y un medicamento que comprenden derivados amino acidos y un factor neutrofico para estimular el crecimiento de neuritas en celulasnerviosas
MX9203677A (es) Derivados ciclicos, medicamentos que contienen estos compuestos y procedimiento para su preparacion.
AR008680A1 (es) Substitutos de plaquetas y metodos de conjugacion apropiados para su preparacion
ES2116131T3 (es) Derivados de naftaleno, su procedimiento de preparacion y productos intermediarios adecuados, y las composiciones farmaceuticas que los contienen.
DK0977874T3 (da) Svækket salmonella-stamme anvendt som bæremedium til oral immunisering
ES2150577T3 (es) Aminoeteres aromaticos como agentes para aliviar el dolor.
AR028504A2 (es) Combinacion, metodo para mejorar la apariencia corporal de un mamifero, composicion farmaceutica, uso de dicha combinacion para la preparacion de un medicamento para la prevencion, demora de progreso, o tratamiento de desordenes metabolicos, y paquete comercial
AR013873A1 (es) Una composicion que comprende derivados de tetralina y factores ico neurologicos para estimular el crecimiento de neuritas en celulas nerviosas
ES2132076T3 (es) Pirroles sustituidos.
NO931526L (no) Cykliske iminoderivater, fremgangsmaate for deres fremstilling, og legemiddelpreparater inneholdende dem
AR016875A1 (es) Un amino-derivado que posee actividad neuronal, una composicion que lo contiene y usos de los mismos para estimular la actividad neuronal
ES2058244T3 (es) Procedimiento para produccion de avermectinas y cultivos para el mismo.
ES2150445T3 (es) Medicamento anti-isquemico.
IL124563A (en) 5-phenyl-3-(substituted oximino) pyrrolo [3, 2-h] isoquinoline-2-one derivatives pharmaceutical compositions containing them and their preparation
ES2120992T3 (es) Derivados de 1-metilcarbapenemo, su preparacion y su uso como antibioticos.
ES2060173T3 (es) Derivados de lisolecitina para el tratamiento de enfermedades autoinmunologicas.
IL145189A0 (en) Synergistic inhibition of viral replication by long-chain hydrocarbons and nucleoside analogs
LTIP610A (en) Inhibitors of cells proliferation, pharmaceutical composition and method for preparation of compounds
DK0907646T3 (da) Dihydrobenzopyren og lignende forbindelser anvendelige som middel mod betændelse
CO4230037A1 (es) Composicion para aplicacion topica a la piel y/o cabello a base de tensioactivo de fosfato y co-tensioactivo
PT701449E (pt) Processo de preparacao de uma forma de dosagem solida oral contendo diclofenac
DK1069912T3 (da) Injicerbare IGF-formuleringer, der indeholder succinat som puffermiddel
AR008695A1 (es) Composiciones farmaceuticas estabilizadas, basadas en la asociacion de quinupristina / dalfopristina; procedimiento para prepararlas, utilizacion dedichas composiciones y utilizacion del acido metansulfonico o del acido clorhidrico en la estabilizacion de dichas composiciones.
EP1074264A4 (en) NEOVASCULARIZATION INHIBITORS
DE60122917D1 (de) Fermentative herstellung von d-p-hydroxyphenylglycin und d-phenylglycin

Legal Events

Date Code Title Description
FB Suspension of granting procedure